Chinese vaccine and biologics maker based in Changchun, with a focus on rabies vaccine and blood-plasma products.
Chinese vaccine and biologics maker based in Changchun, with a focus on rabies vaccine and blood-plasma products.
Moat: narrow (regulatory licence). Licensed rabies-vaccine and plasma production base, competing with larger national players.
Headquarters: Changchun, China · Employees: 1,252
Size Changchun BCHT Biotechnology (688276.SS) is a China Health Care company (Biotechnology) with a market value of $992M, the 2172nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.15 on 18 Nov 2026.
Performance Over six months the shares fell 1.9%, against -15.1% for the median peer and -20.0% for the China market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 2.5% over the last twelve months (peer median +7.8%); the operating margin is -28.8% (peer median -18.3%).
Valuation It trades at 9.9× enterprise value to sales against a peer median of 5.9× (4th most expensive of 15).
Capital Return on invested capital runs 12.3 points below its cost of capital (10.1% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥694M | CN¥603M | CN¥1.22B | CN¥1.82B | CN¥1.07B |
| Revenue growth | — | -51% | -33% | +70% | — |
| Gross profit | CN¥530M | CN¥292M | CN¥1.01B | CN¥1.60B | CN¥904M |
| EBITDA | n/a | -CN¥162M | CN¥364M | CN¥641M | CN¥237M |
| Net income | -CN¥200M | -CN¥263M | CN¥232M | CN¥501M | CN¥182M |
| Free cash flow | -CN¥111M | -CN¥180M | -CN¥138M | -CN¥278M | -CN¥292M |
| Capital expenditure | CN¥403M | CN¥406M | CN¥542M | CN¥471M | CN¥291M |
| Total debt | CN¥513M | CN¥265M | CN¥103M | CN¥20.5M | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Changchun BCHT Biotechnology 688276.SS | $992M | -2% | +2% | -29% | 9.9× | n/a |
| Liaoning Chengda Biotechnology 688739.SS | $1.22B | -14% | -9% | 0% | 2.2× | 6.6% |
| Hualan Biological Engineering 002007.SZ | $3.20B | -17% | -11% | 17% | 5.3× | 15.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688276.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.9% | -8.8% | 4th highest of 21 |
| 6-month return | -1.9% | -15.1% | 7th highest of 20 |
| Distance from 52-week high | -29.9% | -40.8% | 3rd highest of 21 |
| Revenue growth (TTM) | +2.5% | +7.8% | 8th highest of 15 |
| Operating margin | -28.8% | -18.3% | 6th lowest of 15 |
| EV / Sales | 9.9× | 5.9× | 4th most expensive of 15 |
| ROIC minus cost of capital | -12.3 pp | -8.9 pp | 5th lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Changchun BCHT Biotechnology 688276.SS | China | $992M | -2% | +2% | -29% | 9.9× | n/a | n/a |
| SpyGlass Pharma SGP | United States | $993M | +36% | n/a | n/a | n/a | n/a | n/a |
| Inhibrx Biosciences INBX | United States | $1.02B | -37% | +43% | -6,287% | 551.0× | n/a | n/a |
| Alto Neuroscience ANRO | United States | $1.04B | +25% | n/a | n/a | n/a | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.05B | -18% | -24% | -2% | 2.9× | 14.3% | -5.8% |
| Daan Gene 002030.SZ | China | $1.05B | -17% | +1% | -81% | 8.0× | 4.8% | -32.3% |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.06B | -58% | -5% | -181% | 5.6× | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $921M | -16% | +1% | 2% | 1.3× | 6.1% | +4.4% |
| Jade Biosciences JBIO | United States | $1.07B | -34% | n/a | n/a | n/a | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $915M | -28% | -28% | 11% | 14.0× | 39.6% | -16.6% |
| Odyssey Therapeutics ODTX | United States | $912M | +12% | -33% | -5,415% | 204.9× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $909M | -15% | 0% | 22% | 4.2× | 9.2% | +2.3% |
| GNI 2160.T | Japan | $903M | -25% | +44% | -21% | 6.2× | n/a | n/a |
| Vor Biopharma VOR | United States | $1.10B | +15% | n/a | n/a | n/a | n/a | n/a |
| Peptidream 4587.T | Japan | $878M | -3% | +14% | -18% | 6.6× | n/a | n/a |
| Verastem VSTM | United States | $866M | +66% | +650% | -194% | 8.2× | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.15B | -25% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.15B | n/a | n/a | n/a | n/a | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $841M | -15% | +16% | -18% | 4.1× | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 2.0× | 15.3% | +9.9% |
| MeiraGTx MGTX | United States | $813M | -13% | +1,366% | 44% | 1.9× | n/a | n/a |